Navigation Links
New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyl's HNO Donors As Novel Treatments For Heart Failure
Date:10/28/2013

CHAPEL HILL, N.C., Oct. 28, 2013 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the publication of recent findings on the role of a novel pure nitroxyl (HNO) donor in enhancing cardiac function and hemodynamics. These findings, based upon analysis of preclinical and human clinical data from studies of CXL-1020, were published online October 9, 2013, in Circulation: Heart Failure, which is published by the American Heart Association.

"Patients with acute decompensated heart failure (ADHF) present with a complex and often life-threatening clinical syndrome – and new therapeutic advances remain scant. These published data demonstrate the functional improvement in myocardial performance produced by a novel pure HNO donor, and show first-in-human evidence for the potential utility of an HNO donor in heart failure," said Wilson "Bill" S. Colucci, M.D., Thomas J. Ryan Professor of Medicine and Chief of the Cardiovascular Medicine Section at Boston University Medical Center, who served as Chairman of the Steering Committee for the CXL-1020 Phase 2a clinical study.

The data published in Circulation: Heart Failure summarize study findings from two preclinical models as well as a clinical study examining the hemodynamic effects and safety of CXL-1020 at doses of 1–20 mg/kg/min in patients with advanced heart failure hospitalized for invasive hemodynamic monitoring. Investigators reported human data demonstrating that CXL-1020, a novel pure HNO donor, enhanced cardiac systolic function while reducing pulmonary capillary wedge pressure (PCWP) and arterial and venous tone without increasing heart rate. Consistent with the clinical data, direct contractile enhancement from CXL-1020 was observed in isolated myocytes as well as in vivo in experimental canine heart failure models. The investigators concluded that the combination of effects differentiates HNO donors from other classes of inotropes or ino-dilators, and provides a strong rationale for continuing studies to develop donors with optimized pharmacology for the treatment of congestive heart failure.

"Cardioxyl is excited about these results obtained with our first-generation HNO donor, and is poised to expand upon this data as we prepare to bring our second-generation HNO donor into the clinic next year," said Chris Kroeger, M.D., Cardioxyl's President and Chief Executive Officer.

The study is available online, via subscription, at http://circheartfailure.ahajournals.org/content/early/2013/10/09/CIRCHEARTFAILURE.113.000632

About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.


'/>"/>
SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ARUP Laboratories Presents Recent Findings at PAINWeek
2. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
3. Key Findings: Innovations in Ophthalmic Devices - Anterior Segment
4. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
5. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
6. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
7. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
8. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
9. Dr. Kevin Foley to Present DiscGenics Recent Findings at the Lumbar Spine Research Societys Annual Meeting
10. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
11. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):